Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $43.60 Average PT from Brokerages

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has been assigned an average recommendation of “Moderate Buy” from the five brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $43.60.

COLL has been the subject of a number of research reports. Piper Sandler cut their target price on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research report on Friday, January 10th. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, January 10th.

Collegium Pharmaceutical Price Performance

Shares of COLL stock opened at $29.80 on Tuesday. Collegium Pharmaceutical has a 1 year low of $27.28 and a 1 year high of $42.29. The firm’s 50 day moving average is $30.78 and its 200-day moving average is $33.30. The firm has a market capitalization of $938.28 million, a price-to-earnings ratio of 12.84 and a beta of 0.99. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The firm had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. Sell-side analysts forecast that Collegium Pharmaceutical will post 5.62 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Shirley R. Kuhlmann sold 26,067 shares of Collegium Pharmaceutical stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $28.50, for a total value of $742,909.50. Following the sale, the executive vice president now owns 108,137 shares in the company, valued at $3,081,904.50. The trade was a 19.42 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Over the last ninety days, insiders have sold 93,567 shares of company stock valued at $2,774,710. 3.98% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of hedge funds have recently bought and sold shares of the business. Invesco Ltd. grew its stake in shares of Collegium Pharmaceutical by 19.5% during the 4th quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company’s stock valued at $50,876,000 after acquiring an additional 289,335 shares during the period. Janus Henderson Group PLC grew its stake in shares of Collegium Pharmaceutical by 319.4% during the 4th quarter. Janus Henderson Group PLC now owns 291,388 shares of the specialty pharmaceutical company’s stock valued at $8,341,000 after acquiring an additional 221,903 shares during the period. Victory Capital Management Inc. grew its stake in shares of Collegium Pharmaceutical by 43.6% during the 3rd quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock valued at $27,461,000 after acquiring an additional 215,874 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Collegium Pharmaceutical by 173.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after acquiring an additional 175,892 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Collegium Pharmaceutical during the 4th quarter valued at approximately $3,489,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.